Hypothesis

The endometrial stroma contains a BMAL1‑high, PDGFRβ⁺ stromal subpopulation that gates the timed expression of senolytic factors (e.g., FOXO3‑mediated BCL2L13) and suppresses the senescence‑associated secretory phenotype (SASP) through direct inhibition of NF‑κB. When circadian rhythm is disrupted, this subpopulation loses BMAL1 oscillation, leading to constitutive FOXO3 inactivation, reduced senolytic activity, and accumulation of p16^INK4a^‑positive stromal cells that secrete IL‑6 and IL‑8, thereby impairing decidualization and embryo implantation. Restoring circadian drive—either by timed melatonin administration or stromal‑specific BMAL1 overexpression—re‑establishes the senolytic window, clears senescent stromal cells, and rescues receptivity.

Mechanistic Rationale

1. BMAL1 as a transcriptional repressor of NF‑κB – Chromatin immunoprecipitation data show BMAL1 binding to the promoters of NF‑κB target genes (IL6, CXCL8) in stromal cells, recruiting HDAC3 to suppress transcription [4]. Loss of BMAL1 removes this brake, amplifying SASP.
2. FOXO3‑dependent senolytic program – BMAL1 drives rhythmic FOXO3 nuclear translocation, which upregulates BCL2L13 (a BCL‑2 family senolytic) and downregulates BCL2, priming stromal cells for apoptosis when senescent stress arises [5]. Circadian desynchrony blunts FOXO3 cycling, shifting the balance toward survival of damaged cells.
3. Stromal subset specificity – Single‑cell RNA‑seq of proliferative‑phase endometrium reveals a PDGFRβ⁺/CD146⁺ stromal cluster expressing high BMAL1 and low p16^INK4a^. This cluster is absent or shifted toward a senescent phenotype in samples from recurrent‑implantation‑failure patients [1][3].

Testable Predictions

• Prediction 1: In endometrial biopsies from women with normal circadian rhythms, the PDGFRβ⁺/CD146⁺ stromal subset will show antiphasic expression of BMAL1 (peak at ZT6) and FOXO3‑target BCL2L13 (peak at ZT12), whereas the same subset from shift‑workers will lose this rhythm and display elevated p16^INK4a^ and SASP cytokines.
• Prediction 2: Pharmacological synchronization of cultured endometrial stromal cells with 100 nM dexamethasone at circadian time 0 will restore BMAL1/FOXO3 oscillations, reduce SA‑β‑gal positivity by >40%, and increase TIMP3 secretion (a decidualization marker) compared with unsynchronized controls.
• Prediction 3: In vivo, timed melatonin administration (2 mg at ZT0) to aged mice (≥12 months) will increase the proportion of BMAL1high/PDGFRβ+ stromal cells, decrease uterine p16^INK4a^ levels, and improve litter size by at least 30% relative to vehicle‑treated controls.

Experimental Approach

• Collect endometrial stromal cells from volunteers with documented sleep‑wake patterns (norm vs. shift work). Perform CITE‑seq for surface markers (PDGFRβ, CD146) and intracellular staining for BMAL1, FOXO3, p16^INK4a^. Use pseudotime ordering to infer circadian phase from expression of core clock genes.
• In vitro, synchronize primary stromal cells with dexamethasone shock, then sample every 4 h for 48 h for RNA‑seq and phospho‑FOXO3 Western blot; assess senescence via SA‑β‑gal and SASP cytokine ELISA.
• In aged C57BL/6 mice, administer melatonin or vehicle at defined circadian times for 4 weeks; harvest uteri for flow cytometry (PDGFRβ+CD146+), immunofluorescence for BMAL1/p16^INK4a^, and functional assay: embryo transfer and implantation count.

Potential Impact

If validated, this hypothesis would reposition circadian therapeutics—such as timed melatonin, light therapy, or pharmacological clock agonists—as senolytic adjuvants for reproductive aging, offering a non‑invasive strategy to restore endometrial receptivity and extend fertile lifespan.